Progress in small-cell lung cancer: The lowest common denominator

Journal of Clinical Oncology

Volumn 26, Issue 26, 2008, Pages 4236-4238

  Gandara, David R ^a   Lara Jr , Primo N ^a   Natale, Ronald ^b   Belani, Chandra ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; THALIDOMIDE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DRUG MONITORING; DRUG SAFETY; EDITORIAL; HUMAN; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS;

EID: 52049085533     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.2692     Document Type: Editorial

References (13)

1. Hermes A, Bergman B, Bremnes R, et al: Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial. J Clin Oncol 26:4261-4267, 2008
2. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001
3. Niell HB, Herndon JE II, Miller AA, et al: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23:3752-3759, 2005
4. Giaccone G, Debruyne C, Felip E, et al: Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971 B; Silva Study). J Clin Oncol 23:6854-6864, 2005
5. Pujol JL, Breton JL, Gervais R, et al: Thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: An intergroup study FNCLCC cleo04-IFCT 00-01. J Clin Oncol 25:3945-3951, 2007
6. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
7. Beutler E, Gelbart E, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95:8170-8174, 1998
8. Hanna N, Bunn P Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038-2043, 2006
9. Natale R, Lara PN Jr, Crowley JC, et al: S0124: A randomized phase III trial of cisplatin + irinotecan (PI) versus cisplatin + etoposide (PE) in patients (pts) with extensive stage small cell lung cancer (E-SCLC). J Clin Oncol 26:400s, 2008 (suppl; abstr 7512)
10. Lara P, Redman M, Lenz H, et al: Cisplatin (cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. J Clin Oncol 25:390s, 2007 (suppl; abstr 7524)
11. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
12. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non - small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2221-2224, 2006
13. Shouhami RL, Spiro SG, Rudd RM, et al: Oral etoposide for advanced small cell lung cancer: Randomized comparison with intravenous chemotherapy. JNCI 89:577-580, 1997